A new stem cell–derived islet therapy showed insulin independence, restored beta-cell function, and prevented severe hypoglycemia in type 1 diabetes, based on interim results presented at the ADA’s 85th Scientific Sessions.
Enhertu, a HER2-directed antibody-drug conjugate, was approved by the U.S. Food and Drug Administration for pretreated patients with metastatic HR-positive, HER2-low or HER2-ultralow breast cancer based on results from the DESTINY-Breast06 trial.
At EULAR 2025, researchers presented data showing aconitine reduced bone erosion and increased regulatory T cells in a rheumatoid arthritis mouse model.